Literature DB >> 25609328

Current medical management of hereditary angioedema: follow-up survey of US physicians.

Marc A Riedl1, Aleena Banerji2, Richard Gower3.   

Abstract

BACKGROUND: A physician survey conducted in the United States between October 2009 and February 2010 revealed wide variability in hereditary angioedema (HAE) management.
OBJECTIVE: A follow-up survey was conducted to assess the impact of newly available treatment options and investigate changes in HAE care patterns.
METHODS: Between March and June 2013, 6570 physicians were contacted, of whom, 245 HAE-treating physicians responded. Participants completed a 46-question online survey that was closely patterned after the initial survey. Although most data were analyzed descriptively, selected questions underwent statistical analysis to evaluate differences in treatment patterns between the 2 surveys.
RESULTS: Compared with the prior survey, this follow-up survey found that the proportion of physicians who reported danazol as the preferred long-term prophylaxis agent declined from 56% to 23% (P < .00005); conversely, C1-esterase inhibitor increased in this category (20% to 57%; P < .00005). The percentage of attacks self-treated at home increased from 8% to 27% (P < .00005). Decreases were observed in emergency department visits (61% to 54%; P = not significant) and hospitalizations (13% to 3%; P = .0001) for HAE attacks. The percentage of patients perceived by physicians to be very satisfied with HAE treatment increased from 13% to 40% (P < .00005). In 2013, convenience was reported more frequently as an important patient factor that drove long-term prophylaxis choice (27% vs 10%; P < .00005), whereas adverse effects were cited less frequently (16% vs 42%; P < .00005); in both surveys, cost and/or insurance coverage was the greatest driver in this category (43% and 46%).
CONCLUSION: Analysis of these findings suggests that the change in HAE treatment has increased self-treatment at home, decreased emergency department visits and/or hospitalizations, and provided greater patient satisfaction.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antifibrinolytics; C1-INH; Danazol; Hereditary angioedema; Home treatment; Icatibant; Long-term prophylaxis; On-demand therapy; Self-administration; Short-term prophylaxis; ecallantide

Mesh:

Substances:

Year:  2014        PMID: 25609328     DOI: 10.1016/j.jaip.2014.08.017

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

Review 1.  Managing the female patient with hereditary angioedema.

Authors:  Aleena Banerji; Marc Riedl
Journal:  Womens Health (Lond)       Date:  2016-03-15

2.  Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

Authors:  Elyse Murphy; Christine Donahue; Laurel Omert; Stephanie Persons; Thomas J Tyma; Joseph Chiao; William Lumry
Journal:  Nurs Open       Date:  2018-08-28

3.  Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series.

Authors:  Marcus Maurer; Markus Magerl; Emel Aygören-Pürsün; Konrad Bork; Henriette Farkas; Hilary Longhurst; Sorena Kiani-Alikhan; Laurence Bouillet; Isabelle Boccon-Gibod; Mauro Cancian; Andrea Zanichelli; David Launay
Journal:  Allergy Asthma Clin Immunol       Date:  2022-01-13       Impact factor: 3.406

4.  How do patients and physicians communicate about hereditary angioedema in the United States?

Authors:  Gagan Jain; Lauren Walter; Carolyn Reed; Patricia O'Donnell; Jeffrey Troy
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

5.  Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial.

Authors:  Nicolas Javaud; Olivier Fain; Isabelle Durand-Zaleski; David Launay; Laurence Bouillet; Anne Gompel; Alain Sobel; Maguy Woimant; Hasina Rabetrano; Tomislav Petrovic; Frédéric Lapostolle; Isabelle Boccon-Gibod; Paul-Georges Reuter; Philippe Bertrand; Brigitte Coppere; Bernard Floccard; Gisele Kanny; Ludovic Martin; Eric Vicaut; Frédéric Adnet
Journal:  Trials       Date:  2016-04-30       Impact factor: 2.279

6.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Authors:  Veronica Squeglia; Alessandro Barbarino; Maria Bova; Carmela Gravante; Angelica Petraroli; Giuseppe Spadaro; Massimo Triggiani; Arturo Genovese; Gianni Marone
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.